LOTT v. THOMAS JEFFERSON UNIVERSITY

CourtDistrict Court, E.D. Pennsylvania
DecidedOctober 19, 2020
Docket2:18-cv-04000
StatusUnknown

This text of LOTT v. THOMAS JEFFERSON UNIVERSITY (LOTT v. THOMAS JEFFERSON UNIVERSITY) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
LOTT v. THOMAS JEFFERSON UNIVERSITY, (E.D. Pa. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

JAMES LOTT, CIVIL ACTION Plaintiff,

v.

THOMAS JEFFERSON UNIVERSITY, NO. 18-4000 Defendant.

DuBois, J. October 19, 2020

M E M O R A N D U M

I. INTRODUCTION In this employment discrimination case, plaintiff James Lott alleges that his former employer, Thomas Jefferson University (“TJU”) discriminated and retaliated against him on the basis of his disabilities—Attention Deficit Hyperactivity Disorder (“ADHD”) and his history of methamphetamine addiction—and failed to accommodate his disability-related needs. Plaintiff asserts claims of disability discrimination under the Americans with Disabilities Act, 42 U.S.C. §§ 12101, et seq. (“ADA”) and the Pennsylvania Human Relations Act, 43 P.S. §§ 951, et seq. (“PHRA”); retaliation under the ADA, PHRA and Family and Medical Leave Act, 29 U.S.C. §§ 2601, et seq. (“FMLA”); and failure to accommodate under the ADA and PHRA. Presently before the Court is Defendant Thomas Jefferson University’s Motion for Summary Judgment. For the reasons set forth below, the Motion is denied. II. BACKGROUND1 “Plaintiff began his employment with [defendant] in or about November 2011.” Pl.’s Resp. Def.’s Statement Mat. Facts (“Pl.’s Resp. Def.’s SMF”) ¶ 1. “Beginning in January 2016,

1 The facts are presented in the light most favorable to plaintiff. Disputed facts are noted as such. Where appropriate, plaintiff and the defendants’ statements of material facts are cited in lieu of a direct citation to the record. Plaintiff began having attendance difficulties resulting from his escalating abuse of methamphetamine.” Id. ¶ 6. As a result, plaintiff’s supervisor, Kristan Davis issued several verbal and written disciplinary warnings to plaintiff in May and June 2016. See id. ¶¶ 11-22. Shortly thereafter, plaintiff applied for FMLA leave to seek treatment for his methamphetamine abuse. See id. ¶ 27.

On June 15, 2016, plaintiff spoke with a Human Resources representative at TJU about taking FMLA leave. See id. ¶¶ 27-29. After this conversation, he was sent to University Health Services (“UHS”) for a fitness for duty evaluation and a drug screening. See Def.’s Statement Mat. Facts (“Def.’s SMF”) ¶¶ 31, 36. While at UHS, plaintiff met with Dr. Ellen O’Connor and “disclosed that he had recently been abusing methamphetamines; that he had been treated in the past for methamphetamine addiction; that he had been using methamphetamines on and off, but more recently for the previous year. . . .” Pl.’s Resp. Def.’s SMF ¶ 33; O’Connor Dep., 18:24- 20:5. Plaintiff also disclosed that he had “a past medical history of hypertension, ADHD, anxiety and depression” and that he was taking Adderall and Klonopin to treat these conditions,

as prescribed by his primary care provider. See Lott Dep. 129:6-130:7. Plaintiff’s drug screening returned positive results for methamphetamine. Pl.’s Resp. Def.’s SMF ¶ 36; Def.’s SMF ¶ 54. Plaintiff was subsequently approved to take FMLA leave from June 15, 2016 to July 22, 2016. See id. ¶ 60. A. Plaintiff’s Treatment at the Livengrin Foundation On June 22, 2016, plaintiff was referred to the Livengrin Foundation (“The Foundation”), where he was diagnosed with substance use disorder and enrolled in a treatment program. Id. ¶¶ 47-48. “The Foundation gave Lott a welcome packet . . . which explained that The Foundation is an ‘abstinence based program’ and included a list titled ‘MEDICATIONS THAT MUST BE AVOIDED.’” Id. ¶ 49; Def.’s Ex. 21 (capitalization in original). Adderall, an amphetamine, was on that list. See Def.’s Ex. 21. Plaintiff testified that, in accordance with this restriction, he refrained from taking Adderall for the duration of his treatment at The Foundation. See Lott Dep., 186:22-187:19. “Plaintiff participated in therapy sessions three times per week.” Pl.’s Resp. Def.’s SMF ¶ 51.

Plaintiff also testified that at the time of his enrollment, The Foundation recommended that he participate in the intensive outpatient program (IOP) and told him that they would determine whether he needed further treatment upon his completion of the IOP. See Lott Dep. 173:5-20. On the other hand, defendant contends that The Foundation “informed Lott early on in treatment that he was expected to enroll in the general outpatient program (GOP) after the IOP was complete.” Def.’s SMF ¶ 52. Plaintiff never received a written treatment plan, but rather The Foundation communicated his treatment plan to him orally. See Lott Dep., 173:2-4; 183:12-21. B. Plaintiff’s Return to Work/Last Chance Agreement “On July 12, 2016, Lott contacted [Debra] Dix2 to tell her he wanted to return to work while

he continued with his treatment.” Def.’s SMF ¶ 62. Based on his conversation with Dix, “[p]laintiff understood that his employment depended upon whether he continued with his treatment plan and graduated from that treatment plan.” Pl.’s Resp. Def.’s SMF ¶ 64. “On July 20, 2016, [p]laintiff met with O’Connor to discuss his anticipated return to work.” Id. ¶ 69. “Plaintiff informed O’Connor that he was off all prescription medication as a condition of his participation in the IOP at [The Foundation].” Id. ¶ 72. He “also voluntarily submitted to another drug screening and tested negative for amphetamines and methamphetamine.” Def.’s SMF ¶ 76.

2 Dix was an Employee Assistance Program (EAP) counselor, who worked for First Call, an EAP provider to TJU. See Def.’s SMF ¶ 46. “While Lott was in the IOP program, Dix acted as an intermediary between The Foundation and O’Connor to keep her apprised of Lott’s progress.” Id. ¶ 61. “Based on Lott’s progress to that point, [a letter from The Foundation] authorizing Lott to return to work, and Lott’s affirmative representation that he would continue to follow The Foundation’s treatment plan, Dr. O’Connor authorized Lott’s return to work.” Id. ¶ 77. “August 1, 2016 was Lott’s first day back at work after his FMLA leave.” Id. ¶ 78. On August 5, 2016, Aaron Sniderman, Human Resources Business Partner at TJU, presented

plaintiff with a Last Chance Agreement (LCA), which he signed. Pl.’s Resp. Def.’s SMF ¶ 87; Sniderman Dep., 35:23-36:3. The Last Chance Agreement provided, in relevant part: 1. Mr. Lott will, for a period of one (1) year from the date of this Memorandum of Agreement, be subject to random evaluations by University Health Services. Such evaluations may include taking of blood and/or urine to perform drug and alcohol screening tests. Additionally, Mr. Lott agrees that failure to comply with this paragraph will be grounds for immediate termination from employment with Jefferson.

2. Mr. Lott will follow the program of treatment set forth by his treating provider and understands that failure to follow the program will result in termination from employment with Jefferson.

3. Mr. Lott will provide a copy of all recommendations and conditions of treatment or requirements for participation in any program of rehabilitation to University Health Services. Moreover, Mr. Lott will follow the recommendations and conditions of treatment set forth and understands that failure to follow them will result in termination from employment at Jefferson.

4. Mr. Lott will notify University Health Services of any changes to the recommendations and conditions of treatment and understands that failure to do so will result in termination from employment at Jefferson.

Def.’s Ex. 27. “Before Lott signed the LCA, he understood that, if he were called for random drug screening, he would be expected to report for testing as soon as possible.” Def.’s SMF ¶ 85; see Lott Dep. 197:19-198:12. C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Sulima v. Tobyhanna Army Depot
602 F.3d 177 (Third Circuit, 2010)
McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
St. Mary's Honor Center v. Hicks
509 U.S. 502 (Supreme Court, 1993)
E. Michael Salley v. Circuit City Stores, Inc
160 F.3d 977 (Third Circuit, 1998)
Katherine L. Taylor v. Phoenixville School District
184 F.3d 296 (Third Circuit, 1999)
Sally J. Shellenberger v. Summit Bancorp, Inc
318 F.3d 183 (Third Circuit, 2003)
Margaret D. Conneen v. Mbna America Bank, N.A
334 F.3d 318 (Third Circuit, 2003)
Doe v. C.A.R.S Protection Plus, Inc.
527 F.3d 358 (Third Circuit, 2008)
Law v. Garden State Tanning
159 F. Supp. 2d 787 (E.D. Pennsylvania, 2001)
Ronald Ross v. Kevin Gilhuly
755 F.3d 185 (Third Circuit, 2014)
Fasold v. Justice
409 F.3d 178 (Third Circuit, 2005)
Bowers v. National Collegiate Athletic Ass'n
475 F.3d 524 (Third Circuit, 2007)
Schlegel v. Koteski
307 F. App'x 657 (Third Circuit, 2009)
Intervest, Inc. v. Bloomberg, L.P.
340 F.3d 144 (Third Circuit, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
LOTT v. THOMAS JEFFERSON UNIVERSITY, Counsel Stack Legal Research, https://law.counselstack.com/opinion/lott-v-thomas-jefferson-university-paed-2020.